Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW Pharmaceuticals (NASDAQ: GWPH) jumped 11.1% today.
GW Pharmaceuticals recently completed filing for Food and Drug Administration approval of Epidiolex, a cannabidiol medicine that's being evaluated for use in patients with two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome.
IMAGE SOURCE: GW PHARMACEUTICALS.
Source: Fool.com